ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC

ARASENS: tolerability + pharmacokinetic analyses of combo therapy with DARO, ADT and DOC in mHSPCПодробнее

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancerПодробнее

The evolving standard of care for patients with metastatic hormone-sensitive prostate cancerПодробнее

OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENSПодробнее

Role of the addition of docetaxel to ADT in mHSPCПодробнее

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPCПодробнее

Assessing the ARANOTE Trial: Role of Darolutamide in Enhancing ADT for HSPCПодробнее

The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPCПодробнее

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPCПодробнее

ARASENS: dialuramide plus ADT and docetaxel in mHSPC stratified by disease risk + volumeПодробнее

Darolutamide and survival in mHSPC: a plain language summary of the ARASENS studyПодробнее

The role of triplet therapy in men with metastatic castration sensitive prostate cancerПодробнее

ESOU Online: EAU22 highlights in prostate cancerПодробнее

New Treatment Option for Metastatic Hormone-Sensitive Prostate CancerПодробнее

Effect of Darolutamide in Metastatic, Hormone-Sensitive Prostate CancerПодробнее

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022Подробнее

Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Подробнее

Future developments in the treatment of prostate cancerПодробнее

Is There Still a Role for Docetaxel in mHSPC?Подробнее